The use of methotrexate in the treatment of selected autoimmune connective tissue diseases — our own experience and review of the literature data

Abstract

Methotrexate (MTX) belongs to the most commonly used immunosuppressants in dermatology. Correct classification of the patient, taking into account possible contraindications may minimize the risk of adverse effects of MTX, while the emergence of new forms for applications of MTX — subcutaneous prefilled syringes — significantly improved bioavailability
compared to oral treatment and allowed to increase the efficacy and safety of the treatment. We present our experience with the use of subcutaneous MTX in the treatment of chronic cutaneous lupus erythematosus (Discoid Lupus Erythematosus, DLE) and in generalized as well as deep forms of morphea. In addition, we reviewed the literature and current guidelines regarding treatment of both diseases.